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The presence of multifocality and the aggregate tumor size were retrospectively analysed in a database of 1071 operated
breast cancers. Around a quarter of all these cancers involved multiple foci, while a tenth of the total demonstrated more 
than one invasive focus. Although the multifocal cancers were smaller and more often screen-detected than the unifocal
cancers, their aggregate tumor size was larger, and they more frequently displayed casting-type calciﬁcations in the mam-
mogram and HER2 positivity. Lobular histology favoured larger tumor burden. The invasive multifocal cancers were more
commonly lymph node-positive than the other tumors. In a subgroup of 584 patients with a median follow-up time of 5 years, 
the larger size of the invasive tumor, the presence of LVI or lymph node involvement, HER2 positivity and triple negativity 
were associated with a poorer RFS and OS, while the outcome of screen-detected tumors was superior to that of non-screen-
detected or interval cancers. A large tumor size, lymph node positivity and HER2 positive or triple negative phenotypes were 
independent determinants of a poorer survival rate. 
Key words: breast cancer, multifocality, prognostic factor, tumor burden
Breast carcinoma is a diverse disease entity, and the therapy 
should be based on speciﬁc markers reﬂecting its individual
biological behaviour [1-3]. The tumor stage is one of the
most relevant factors determining the outcome. The currently
used prognostic factors, however, do not reliably distinguish 
between true early breast cancers (usually screen-detected 
and small, with a cure rate of around 95%), and those that 
exhibit an apparently low TNM status, but in fact are at 
a more advanced stage with a high risk of relapse [3-6]. Since 
the panorama of breast cancers in the era of mammographic 
breast screening is even more heterogeneous than previously, 
intensive investigations have been devoted to the identiﬁcation
of new factors that might facilitate prognosis prediction, and 
could assist decision-making concerning adjuvant therapy. 
Features that have been considered include the mode of detec-
tion [4, 6, 7], the mammographic appearance of the tumor [2, 
8], and the subgross morphology of the tumor, including the 
distribution and the extent of the lesion [9, 13]. 
The prognostic signiﬁcance of multifocality/multicentricity
and the tumor burden have long been the subjects of inves-
tigation, but the results are inconclusive as the nomenclature 
and methods applied were not uniform [1, 12-17]. In general, 
multifocality is deﬁned as the presence of two or more tumor
foci separated by normal breast parenchyma. Some studies 
have attempted to take into consideration the entire tumor 
burden from the aspect of the outcome, by using the aggregate 
measure of the dimensions or volumes of the tumor foci [9, 
10, 14, 16]. A larger tumor burden due to multifocality has 
been related to poorer pathological characteristics [1, 12, 14], 
relapse-free survival [12, 17] and survival [12, 15, 16, 18]. In 
the case of multifocal breast cancers, therefore, a consideration 
of the TNM stage alone, would lead to inaccurate conclusions 
during treatment decision-making. 
Our aims in the present study were to evaluate how the 
multifocality and calculated tumor burden in operable breast 
carcinomas relate to conventional pathological and other tu-
mor features, and to assess their eﬀects on the outcome.
Patients and methods 
Study population. The patient- and tumor-related data on
women attending the Breast Unit at the University of Szeged 
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with invasive breast cancer in clinical stage I or II between 
May 2004 and August 2010 were prospectively collected. All 
these patients underwent primary breast surgery, and adjuvant 
therapy was administered in accordance with the national and 
international guidelines. 
Prospective data collection. The data recorded were the
age of the patient at the time of breast surgery, the mode of 
detection of the breast cancer (mammography screening-
detected, detected other than by mammography screening or 
interval cancer) and its mammographic appearance, classiﬁed
as published earlier [2, 19]. Brieﬂy, the radiologic images were
categorized as stellate (spiculated) tumor masses, circular 
tumors, and parenchymal dystorsion/asymmetric density, 
while malignant microcalciﬁcations were categorized into
two groups: casting-type calciﬁcations and non-casting-type
calciﬁcations. For the analysis of the association between the
mammographic image and survival, these categories were 
grouped as: stellate lesions without casting-type calciﬁcations,
casting-type calciﬁcations with or without an associated tumor
mass and others. The type of breast surgery (breast-conserv-
ing surgery vs. mastectomy), the type of lymph node surgery 
(sentinel lymph node biopsy vs. axillary lymph node dissection 
with or without sentinel lymph node biopsy), the pathological 
size of the largest invasive focus (pT), the histological type, the 
histological grade, the presence of lymphovascular invasion 
(LVI) and the information on lymph node involvement were 
also compiled. The percentages of cells expressing the oestro-
gen receptor (ER), the progesterone receptor (PR), Ki67 and 
topoisomerase2-alpha (TOP2A) protein were routinely deter-
mined by means of immunohistochemistry [20]. A cut-oﬀ
value of ≥10% was used for ER or PR positivity, and >15% for 
TOP2A or Ki67 positivity. The HER2 status was determined
via immunohistochemistry and/or HER2 FISH [20]. Immu-
nohistochemistry data were not available for all patients.
Retrospective data collection. Additionally, we retro-
spectively extracted the following data from the pathological 
reports: the presence of multifocality, the sizes of the multiple 
foci (both invasive and in situ foci, if present), and the grade 
of the in situ component, if present. Pathological reports were 
considered only if there was a clear allusion to the presence 
or absence of more than one tumor focus. In all cases, large-
format histological sections (maximum size 60x90 mm) were 
examined according to Tot (21). The criterion of multifocality
was the presence of more than one cancer focus separated by 
non-malignant breast tissue. If two or more invasive foci were 
present, the tumor was classiﬁed as invasive multifocal. Since
most of the pathological reports did not provide the extent 
of the breast parenchyma involved by malignant structures, 
the pathological extent of the disease was estimated by sum-
ming the largest diameters of the invasive and in situ cancer 
foci; this measure was taken as the tumor burden. In unifocal 
cases, the tumor size comprised the tumor burden. Analyses 
were made on the basis of the presence of multifocality, the 
magnitude of the tumor burden, other pathological features 
and the survival data. 
Survival data. Survival data were collected on the basis 
of regular 6-month follow-up visits or events such as relapse 
or death. Relapse-free survival (RFS) was deﬁned as the time
from breast surgery to any instance of disease recurrence (lo-
cal, regional or distant relapse or a contralateral breast cancer). 
Breast cancer-speciﬁc survival (BCSS) was deﬁned as the time
from breast surgery to death of breast cancer. For the survival 
analyses, we excluded patients operated on after 2007. RFS
and BCSS were studied in relation to the patient and tumor 
characteristics; the median value (19 mm) of the tumor burden 
was applied as a cut-oﬀ value. In order to detect a diﬀerence in
outcome between the apparently early (cancers <15 mm) and 
more advanced cases as a function of the studied variables, 
survival analysis was performed separately on a subgroup of 
patients with breast cancers measuring <15 mm, regardless of 
whether they were unifocal or multifocal. 
Statistical analyses. For the categorical parameters, the 
chi-square test was applied; for the analysis of continuous data, 
variance analysis and the Kruskal-Wallis test were used. The
eﬀects of the diﬀerent patient and pathological characteristics
on the disease outcome were assessed with the Kaplan-Meier 
method, and the eﬀects of the various tumor-related factors on
the disease outcome were evaluated with the Cox proportional 
hazards model. Statistical analysis was performed with SPSS 
15.0 for Windows. 
Results
Among a total of 1234 breast carcinoma cases, 1071 were 
eligible for the analysis. The mean (±SD) age was 58.6±12.0
(range 24.5-88.6) years. The patient and tumor characteristics
are presented in Tables 1 and 2. Around 40% of the cases were 
screen-detected. 
Multifocality. Among the 796 (74.3%) unifocal and 275 
(25.7%) multifocal cancers found, there were 101 multifocal 
invasive tumors, while in 174 cases a single invasive focus was 
associated with one or more in situ foci. Multifocal cancers 
were more susceptible to screen detection, HER2 positivity and 
casting calciﬁcations in the mammogram than were unifocal
cancers. Invasive multifocality was more strongly associated 
than non-invasive multifocality with mastectomy (44% vs. 
28%, p<0.01), lymph node positivity (47 vs. 35%, p=0.03) and 
HER2 positivity (17 vs. 9%, p=0.02). The maximum diameter
of unifocal cancers was than the largest tumor focus in multi-
focal cancers (p<0.001). 
Tumor burden. The calculated mean (±SE) tumor burden in
the unifocal and the multifocal cases was 19.5±0.4 and 31.2±0.9, 
respectively (p<0.001). We analysed the standard pathological 
parameters according to the tumor burden, using the median 
value of 19.0 mm as a threshold (Table 3). The presence of lymph
node metastases (p<0.001) or LVI (p<0.001) was associated 
with a larger tumor burden. The mean (±SE) tumor burden
was 21.7±0.4 vs. 28.9±1.4 mm in invasive ductal vs. lobular 
carcinomas, respectively (p<0.01). A larger invasive tumor 
focus and a larger tumor burden predisposed to ER, PR nega-
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Table 1. Patient-, tumor- and surgery-related parameters in unifocal and multifocal cancers
Variable Unifocal cancers 
(n=796) (%)
Multifocal cancers 
(n=275)
(%)
p All
(n=1071)
(%)
Age (mean±SD) 58.7±12.2 58.5±11.5 0.87 58.6±12.0
Mode of detection Screen-detected
Symptomatic+interval
312 (39.2)
484 (60.8)
130 (47.3)
145 (52.7)
0.02 442 (41.3)
629 (58.7)
Mammographic appearance Stellate
Casting-type calciﬁcation±tumor mass
Other
308 (39.1)
35 (4.4)
444 (56.4)
78 (28.4)
51 (18.5)
146(53.1)
<0.001 386 (36.3)
86 (8.1)
590 (55.6)
Breast surgery Excision
Mastectomy
570 (71.6)
226 (28.4)
186 (67.6)
89 (32.4)
0.22 756 (70.6)
315 (29.4)
Lymph node surgery SNB or nothing
ABD±SNB
382 (48.0)
414 (52.0)
139 (50.5)
136 (49.5)
0.48 382 (48.6)
414 (51.4)
Table 2. Routinely assessed pathological parameters among unifocal, multifocal and invasive multifocal cancers
Variable Unifocal 
cancers 
(n=796) 
(%)
Multifocal  
cancers 
(n=275) (%)
p (multifocal 
versus unifo-
cal)
All
(n=1071)
(%)
Invasive 
multifocal 
cancers 
(n=101) 
(%)
p 
(invasive 
multifocal 
versus  
unifocal)
All
(n=897)
(%)
Tumor size (mean±SD) 19.5±10.8 16.3±9.6 <0.001 18.6±10.6 18.1±10.1 0.24 19.3±10.7
Lymph node status N-
N+
510 (64.1)
286 (35.9)
173 (62.9)
102 (37.1)
0.77 683 (63.8)
388 (36.2)
54 (53.5)
47 (46.5)
<0.05 564 (62.9)
333 (37.1)
Histological type of the 
invasive component
Invasive ductal carcinoma
Invasive lobular cancer
Other
620 (77.9)
93 (11.7)
83 (10.4)
220 (80.0)
32 (11.6)
23 (8.4)
0.61 840 (78.4)
125 (11.7)
106 (9.9)
77 (76.2)
18 (17.8)
6 (5.9)
0.10 697 (77.7)
111 (12.4)
89 (9.9)
Grade
Grade 1
Grade 2 or 3
113 (14.3)
676 (85.7)
45(16.5)
228 (83.5)
0.38
n=1062
158 (14.9)
904 (85.1)
16 (16.2)
83 (83.8)
0.65
n=888
129 (14.5)
759 (85.5)
Presence of DCIS
Grade 1
Grade 2
Grade 3 
n=295
40 (13.6)
85 (28.8)
170 (57.6)
n=197
24 (12.2)
49 (24.9)
124 (62.9)
0.49
n=492 
4 (13.0)
134 (27.2)
294 (59.8)
n=58 
9 (15.5)
25 (43.1)
24 (41.4)
0.06
n=353
49 (13.9)
110 (31.2)
194 (55.0)
Presence of LVI LVI-
LVI+
648 (81.4)
148 (18.6)
224 (81.5)
51 (18.5)
1.00 872 (81.4)
199 (18.6)
88 (87.1)
13 (12.9)
0.17 736 (82.1)
161 (17.9)
ER status
ER+
ER-
606 (76.5)
186 (23.5)
198 (72.0)
77 (28.0)
0.14
n=1067
804 (75.4)
263 (24.6)
78 (77.2)
23 (22.8)
1.00
n=893
684 (76.6)
209 (23.4)
PR status
PR+
PR-
565 (70.9)
231 (29.1)
180 (65.5) 
95 (34.5)
0.09
n=1069
743 (69.5) 
326 (30.5)
70 (69.3)
31 (30.7)
0.73
n=895
633 (70.7)
262 (29.3)
Ki67 status
Ki67+
Ki67-
119 (40.8)
173 (59.2)
37 (52.9)
33 (47.1)
0.08
n=362
156 (43.1)
206 (56.9)
15 (51.7)
14 (48.3)
0.32
n=321
134 (41.7)
187 (58.3)
TOP2A status
TOP2A+
TOP2A-
59 (26.6)
163 (73.4)
19 (31.1)
42 (68.9)
0.52
n=283
78 (27.6)
205 (72.4)
8 (32.0)
17 (68.0)
0.64
n=247
67 (27.1)
180 (72.9)
HER2 status
HER2+
HER2-
58 (7.4)
723 (92.6)
46 (17.2)
221 (82.8)
<0.001
n=1048
104 (9.9)
944 (90.1)
17 (17.3)
81 (82.7)
0.003
n=879
75 (8.5)
804 (91.5)
Triple negativity
Yes
No
106 (13.4)
683 (86.6)
26 (9.5)
248 (90.5)
0.09
n=1063
132 (12.4)
931 (87.6)
7 (6.9)
94 (93.1)
0.08
n=890
113 (12.7)
777 (87.3)
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tivity (p<0.001) and HER2 positivity (p<0.001). In multivariate 
analysis, only the connections between the tumor burden and 
ER, PR negativity and HER2 positivity remained signiﬁcant
(p<0.001). A larger tumor burden was associated with Ki67 
positivity (p=0.02). A tumor burden larger than the cut-oﬀ value
was related to multifocality (p<0.001). The mean (±SE) tumor
burden was 32.6±0.2 mm in cases where there were casting 
calciﬁcations in the mammogram, and 20.9±0.6mm when the
lesion was categorized as a spiculated mass (p<0.001). 
Survival. The median follow-up time for the population
of 584 patients participating in the survival analysis was 
5.0 (range 0.3-7.3) years, while that in the subgroup of 233 
patients with cancers measuring <15 mm, was 5.2 (0.5-7.3) 
years. In the overall population, there were 65 relapses (12.7%) 
and 30 deaths (5.8%), while among the patients with cancers 
measuring <15 mm in size, there were 11 relapses (5.5%) and 
2 deaths (1.0%). In the overall population, the numbers of 
relapses and deaths in the multifocal vs. the unifocal cases, 
respectively were 17 vs. 48 and 7 vs. 23. The survival data did
not diﬀer as a function of the presence of multifocality in the
entire population or in the subgroup with cancers <15 mm in 
size (Table 4). In the latter group, the OS analysis was omitted 
because of the low number of events.
Among the conventional tumor characteristics including 
the histological type, the expression of hormone receptors and 
the Ki67 and HER2 status, only a larger invasive tumor, the 
presence of LVI or lymph node involvement, HER2 positiv-
ity and triple negativity were associated with a poorer RFS 
and OS (Table 4). The grade of the invasive tumor was not
related to the RFS. As regards the mode of detection, screen-
detected tumors gave RFS and OS statistics that were superior 
to those for non-screen-detected or interval cancers. The
mammographic appearance of the tumor was not related to 
the outcome. A tumor burden >19 mm or >40 mm (extensive 
tumor) involved a shorter RFS and OS. Neither multifocality 
nor invasive multifocality was associated with a shorter RFS 
or OS. Among tumors <15 mm in size, only HER2 positivity 
was related to a poorer RFS.
In Cox proportional hazards models, the largest invasive 
tumor size, the lymph node status, triple negativity and HER2 
positivity remained independent determinants of an increased 
risk of relapse or death (Tables 5 and 6). 
Discussion
Our analysis indicated that, although multifocal breast 
tumors (frequently screen-detected) are often smaller than
unifocal breast tumors, the aggregate size and hence the 
load of the cancer are larger, as an indication of a higher risk 
of dissemination. The relatively high proportion of lymph
Table 3. Routinely assessed pathological parameters in 1071 breast cancers according to tumor burden 
Variable Tumor burden≤19 mm 
(n=536)
Tumor burden>19 mm 
(n=535)
p
Tumor size (mean±SD) 12.4±3.9 24.9±11.4 <0.001
Lymph node status N-
N+
383 (71.5)
153 (28.5)
300 (56.1)
235 (43.9)
<0.001
Histological type Invasive ductal carcinoma
Invasive lobular cancer
Other
437 (81.5)
46 (8.6) 
53 (9.9)
403 (75.3)
79 (14.8)
53 (9.9)
0.01
Grade Grade 1
Grade 2 or3 
118 (22.2)
411 (77.8)
40 (7.5)
490 (92.5)
<0.001
Presence of DCIS
Grade 1
Grade 2
Grade 3 
n= 219 (44.5% of all)
44 (20.1)
69 (31.5)
106 (48.4)
n=273 (55.5% of all)
20 (7.3)
65 (23.8)
188 (68.9)
<0.001
Presence of LVI LVI-
LVI+
460 (85.8)
76 (14.2)
412 (77.0)
123 (23.0)
<0.001
ER status
n=1067
ER+
ER-
436 (82.0)
96 (18.0)
368 (68.8)
167 (31.2)
<0.001
PR status
n=1069
PR+
PR-
403 (75.5)
131 (24.5)
340 (63.6)
195 (36.4)
<0.001
Ki67 status
n=362
Ki67+
Ki67-
76 (37.4)
127 (62.6)
80 (50.3)
79 (49.7)
0.02
TOP2A status
n=283
TOP2A+
TOP2A-
38 (24.7)
116(75.3)
40 (31.0)
89 (69.0)
0.29
HER2 status n=1048 HER2+
HER2-
39 (7.4)
486 (92.6)
65 (12.4)
458 (87.6)
0.01
Multifocality
n=1071
Yes
No
60 (11.2)
476 (88.8)
215 (40.2)
320 (59.8)
<0.001
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Table 4. The eﬀects of selected variables on disease outcome (median RFS and OS) among the cases participating in the survival analysis, and in the
subgroup of patients with tumors <15 mm  
Overall population (n=584) pT < 15 mm (n=233)
RFS
estimated mean (±SE, years)
OS
estimated mean (±SE, years)
RFS
estimated mean (±SE, years)
Largest invasive tumor
<15 mm 7.0±0.1 7.3±0.0 -
≥15 mm 6.4±0.1 6.9±0.1 -
p (Mantel-Cox) <0.001 <0.001 -
Lymph node positivity
Yes 6.1±0.2 6.8±0.1 6.6±0.3
No 7.0±0.1 7.2±0.0 7.2±0.1
p (Mantel-Cox) <0.001 <0.001 =0.08
Invasive tumor grade
1 6.9±0.2 7.3* 7.0±0.2
2 or 3 6.6±0.1 6.9±0.6 6.9±0.1
p (Mantel-Cox) =0.17 =0.03 =0.80
Presence of LVI
Yes 6.2±0.2 6.7±0.1 6.2±0.3
No 6.8±0.1 7.2±0.1 7.1±0.1
p (Mantel-Cox) =0.02 =0.004 =0.31
HER2  
Positive 5.7±0.4 6.3±0.2 5.8±0.6
Negative 6.7±0.1 7.1±0.1 7.1±0.1
p (Mantel-Cox) <0.001 <0.001 <0.001
Triple negative 
Yes 6.0±0.3 6.5 ±0.2 6.4±0.3
No 6.7±0.1 7.1±0.1 7.1±0.1
p (Mantel-Cox) =0.02 =0.002 =0.31
Mode of detection
Screen-detected 6.9±0.1 7.2±0.1 7.1±0.1
Interval and non-screen-detected cancer 6.4±0.1 6.9±0.1 6.9±0.2
p (Mantel-Cox) =0.001 =0.01 =0.69
Mammographic appearance
Spiculated tumor mass without casting calciﬁcation 6.7±0.1 7.1±0.1 7.2±0.1
Casting calciﬁcation ± tumor mass 6.4±0.3 6.9±0.2 6.0±0.4
Other 6.7±0.1 7.1±0.1 6.9±0.1
p (Mantel-Cox) =0.66 =0.70 =0.49
Multifocality
Yes 6.6±0.1 7.0±0.1 6.9±0.1
No 6.7±0.1 7.1±0.1 7.0±0.1
p (Mantel-Cox) =0.45 =0.59 =0.93
Invasive multifocality
Yes 6.5±0.3 7.1±0.1 6.2±0.4
No 6.7±0.1 6.9±0.1 7.1±0.1
p (Mantel-Cox) =0.94 =0.70 =0.12
Tumor burden
≤19 mm 6.7±0.1 7.1±0.1 6.8±1.1
>19 mm 6.5±0.1 6.9±0.1 7.3*
p (Mantel-Cox) =0.09 =0.03 =0.09
Tumor burden
<40 mm 6.7±0.1 7.1±0.1 7.0±0.1
≥40 mm 5.9±0.3 6.5±0.2 7.0*
p (Mantel-Cox) =0.04 =0.02 =0.42
*All cases are censored
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node-positive cases in invasive multifocal cancers reﬂects
their aggressive behaviour and advanced stage. Although our 
results do not support the role of multifocality as an independ-
ent predictor of a worse prognosis, they should warn against 
the consideration of only a single tumor focus rather than the 
whole extent of the disease if multiple cancer foci are present 
so as to avoid false judgement. It is important that multifocal 
breast cancers are a special type with a poorer prognosis; they 
are often HER2- positive and associated with casting-type
microcalciﬁcations in the mammogram. Lobular histology
favoured larger tumor burden. 
In our study, multifocality and “invasive multifocality” 
occurred within the ranges reported by other authors [16, 
18, 22]. There are a number of reasons how to explain the
discrepancies between the ﬁndings. Some authors do not
distinguish between multicentric (situated in diﬀerent quad-
rants of the breast) and multifocal cancers [12], and include 
tumors with a single invasive focus and in situ components 
[18], whereas others regard tumors as multifocal only if 
more than one invasive focus is present [1, 11, 13-16, 18]. 
The strength of our study is that we relied on data recorded
in thorough examinations of large-format histopathology 
slides. Nonetheless the retrospective nature of the study is 
a disadvantage. 
The UICC/AJC TNM system is used as a prognostic tool,
and the TNM stage has long served as the basis of therapy 
decision-making. A major ﬂaw is that, in cases of multifo-
cality, the T stage indicates the largest invasive focus of the 
disease, but ignores the eﬀective tumor burden, which may be
signiﬁcant if multiple foci are present. Our study accords with
the ﬁndings of others in that the TNM system in its current
form is not suitable for these purposes in the population of 
multifocal breast cancers [9, 11, 12, 15, 23, 24]. We found that, 
despite the tumor being smaller, lymph node positivity was 
Table 5. The eﬀects of selected patient- and tumor-related features on the risk of relapse according to the Cox proportional hazards model: univariate
and multivariate analysis 
Variable Univariate 
HR (95% CI)
p Multivariate HR (95% CI) p
pT ≥15 vs. <15 mm 3.4 (1.8-6.5) <0.001 2.0 (1.0-4.0) 0.05
Lymph node-positive vs. lymphnode-negative 3.8 (2.3-6.4) <0.001 3.0 (1.7-5.3) <0.001
Grade 2-3 vs. grade 1 (invasive component) 1.9 (0.8-4.7) 0.17
Presence of LVI 1.8 (1.1-2.9) 0.02 1.1 (0.6-1.7) 0.97
HER2 positivity 2.9 (1.7-5.3) <0.001 3.1 (1.7-5.8) <0.001
Triple negativity 1.8 (0.9-3.4) 0.06 2.2 (1.1-4.4) 0.02
Non-screen-detected or interval vs. screen-detected 2.5 (1.4-4.3) <0.001 1.6 (0.9-2.8) 0.15
Casting calciﬁcation vs. spiculated tumor mass 1.5 (0.6-3.8) 0.37
Spiculated tumor mass vs. other 1.1 (0.7-1.9)   0.69
Presence of multifocality 0.8 (0.5-1.4) 0.45
Tumor burden >19 mm 1.5 (0.9-2.6) 0.09
Tumor burden >40 mm 1.8 (1.1-3.4) 0.05 1.0 (0.5-2.0) 0.98
       
Table 6. The eﬀects of selected patient- and tumor-related features on the risk of death due to breast cancer according to the Cox proportional hazards
model: univariate and multivariate analysis 
Category Univariate 
HR (95% CI)
p Multivariate HR (95% CI) p
pT  ≥15 vs. <15 mm 8.9 (2.1-37.7) 0.03 2.5 (1.2-5.2) 0.03
Lymph node positivity 5.0 (2.1-11.9) <0.001 3.3 (1.4-8.2) 0.01
Grade 2-3 vs. grade 1 (invasive component) 25.2 (0.2-3012.88) 0.18
Presence of LVI 2.9 (1.3-6.1) 0.01 1.3 (0.6-3.0) 0.48
HER2 positivity 5.8 (2.6-12.7) <0.001 8.4 (3.2-22.1) <0.001
Triple negativity 3.5 (1.5-8.1) 0.003 6.8 (2.5-18.5) <0.001
Non-screen-detected or interval vs. screen-detected 3.7 (1.4-9.6) 0.01 2.3 (0.8-6.9) 0.13
Casting calciﬁcation vs. spiculated tumor mass 1.7 (0.5-6.4) 0.42
Spiculated tumor mass vs. other 1.3 (0.5-3.0) 0.59
Presence of multifocality 0.8 (0.3-1.9) 0.59
Tumor burden >19 mm 2.6 (1.1.-6.1) 0.03 0.8 (0.3-2.1) 0.65
Tumor burden >40 mm 2.6 (1.1-6.2) 0.03 0.9 (0.3-2.7) 0.94
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more prevalent among cancers containing multiple invasive 
foci, and a larger aggregate tumor burden involved a poorer 
outcome. These results are in accordance with those [9, 10, 12,
14, 16, 18] indicating that multifocality is related to lymph node 
positivity. Moreover, Tot et al. found multifocal and diﬀuse
lesion distribution to be an independent predictor of breast 
cancer-related fatality [18]. In fact, the diﬀuse distribution
of the lesions is a rarely described phenomenon, and conse-
quently its eﬀect should rather be analysed prospectively [23].
We could not recover this type of tumor from the pathology 
records; such cases were probably classiﬁed as unifocal, which
could play a role in the incongruence between the ﬁndings of
Tot et al. and ourselves [18]. Nevertheless, our results conform 
to the view that a consideration of multifocality is demanded 
in every breast cancer specimen. 
For the estimation of tumor extent, we calculated the tu-
mor burden by summing the largest diameters of the tumor 
foci. This method provides merely an approximation; only
exact measurement of the entire tumor extent, encompass-
ing the whole of the aﬀected part of the breast parenchyma,
would furnish accurate information. For the estimation of 
tumor burden, diﬀerent approaches have been utilized in the
literature. For assessment of the tumor burden of multifocal 
cancers and the eﬀect on survival, Rezo et al. used aggregate
sizes and volumes of the tumor foci, calculated as though 
they were spherical [16]. Interestingly, all measures gave 
similar results: increasing tumor size predicted a poorer 
outcome after 60 months of follow-up. Others followed the
same method as we did, using the combined diameters of 
the tumor foci [9, 11, 14]. 
The effect of multifocality on prognosis is controver-
sial. Similarly to our findings, Cabioglu et al. concluded 
that the presence of multiple invasive foci favoured lymph 
node positivity, and the 55 month-survival did not differ 
between multifocal and unifocal cases [14]. Yerushalmi 
et al. analysed a dataset on more than 25,000 cases, and 
found that multifocality carried a 17% extra risk of breast 
cancer-related death in stage I-III breast cancers [15]. In 
a matched-pair analysis of 288 breast cancer cases, Weis-
senbacher et al likewise showed that both the risk of relapse 
and that of death due to breast cancer were increased in 
multifocal cancers [12]. Boyages et al. demonstrated a better 
10-year survival rate among unifocal breast cancer cases 
than among multifocal breast cancer cases, but this effect 
was restricted to tumors >20 mm [11]. In a series of 574 
breast cancer cases, Tot et al. observed a significantly poorer 
breast cancer-specific survival rate in multifocal cancers, 
irrespective of whether only invasive or invasive plus in 
situ multifocal cases were included [18]. We did not detect 
a difference in survival between the cases with multifocal 
and unifocal breast cancers, but tumor size, lymph node 
status and HER2-positive or triple negative status were 
independent predictors of outcome. The relatively low 
overall number of events and short follow-up times could 
have played a role in these results.
Conclusions
For the adequate management of breast cancer, an ap-
propriate assessment of the tumor distribution is essential; 
heightened attention is needed during the care of multifocal 
breast cancers, which present in a more advanced stage than 
estimated from the consideration of only the largest focus. 
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